Evidence map›Paper›PMID 38473953›Full record

ArticleInternational journal of molecular sciences2024

Molecular Targets of the 5-Amido-Carboxamide Bumped Kinase Inhibitor BKI-1748 in

Jubilee Ajiboye, Anne-Christine Uldry, Manfred Heller, Arunasalam Naguleswaran, Erkang Fan, Wesley C Van Voorhis, Andrew Hemphill, Joachim Müller

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Proteome changes duringFrontiers in cellular and infection microbiology · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Jubilee AjiboyeInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, 3012 Bern, Switzerland.
Anne-Christine UldryProteomics and Mass Spectrometry Core Facility, Department for BioMedical Research (DBMR), University of Bern, Länggass-Strasse 122, 3012 Bern, Switzerland.ORCID 0000-0003-2820-0277
Manfred HellerProteomics and Mass Spectrometry Core Facility, Department for BioMedical Research (DBMR), University of Bern, Länggass-Strasse 122, 3012 Bern, Switzerland.ORCID 0000-0002-6364-7325
Arunasalam NaguleswaranInstitute of Molecular Pathology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, 3012 Bern, Switzerland.ORCID 0000-0002-9509-485X
Erkang FanDepartment of Biochemistry, University of Washington, Seattle, WA 98109, USA.
Wesley C Van VoorhisCenter for Emerging and Re-Emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA.ORCID 0000-0001-6141-2015
Andrew HemphillInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, 3012 Bern, Switzerland.ORCID 0000-0002-0622-2128
Joachim MüllerInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, 3012 Bern, Switzerland.ORCID 0000-0001-8189-9270
University of Bern · CHUniversity of Washington · USUniversity of Vermont · US

Funding

Optimization of Lead BKIs for Cryptosporidiosis TherapyR01AI155412 · NIAID · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2021 to 2025
$4.1M
Bumped-Kinase Inhibitor Drug Development for ToxoplasmosisR01HD102487 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2021 to 2025
$3.3M
Dual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and NeosporosisR01HD080670 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$1.9M
Repurposing the EMD-Serono "mini-library" for Cryptosporidium drug developmentR33AI141184 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HUSTON, CHRISTOPHER D, MEYERS, MARVIN J · 2021 to 2023
$1.3M
NIAID NIH HHS R01 AI155412NIAID NIH HHS R33 AI141184NICHD NIH HHS R01 HD080670NICHD NIH HHS R01 HD102487NIH HHS 1R01AI155412-01NIH HHS R01HD102487Swiss National Science Foundation 310030_184662
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsAntiprotozoal AgentsCryptosporidiosisCryptosporidiumCryptosporidium parvumAnimalsHumansQuinineAntineoplastic AgentsAntiprotozoal AgentsQuinineaffinity chromatographybinding proteinsproteomicsside effectssplicing

Identifiers

PMID38473953
PMCPMC10931551
OpenAlexW4392155188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.